Yael A Leshem
Overview
Explore the profile of Yael A Leshem including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
31
Citations
315
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Haag C, Alexis A, Aoki V, Bissonnette R, Blauvelt A, Chovatiya R, et al.
Br J Dermatol
. 2024 Sep;
192(1):135-143.
PMID: 39250758
Background: Janus kinase inhibitors (JAKi) have the potential to alter the landscape of atopic dermatitis (AD) management dramatically, owing to promising efficacy results from phase III trials and their rapid...
2.
Jacobson M, Leshem Y, Apfelbacher C, Spuls P, Gerbens L, Thomas K, et al.
JAMA Dermatol
. 2024 May;
160(8):878-886.
PMID: 38776110
Importance: Outcome measurement is an essential component of value-based health care and can aid patient care, quality improvement, and clinical effectiveness evidence generation. The Harmonising Outcome Measures for Eczema Clinical...
3.
Simpson E, Prajapati V, Leshem Y, Chovatiya R, de Bruin-Weller M, Stander S, et al.
Dermatol Ther (Heidelb)
. 2024 May;
14(5):1127-1144.
PMID: 38696027
Introduction: Atopic dermatitis (AD) is characterized by intense itch and other symptoms that negatively impact quality of life (QoL). This study evaluates the effect of upadacitinib (an oral selective Janus...
4.
Thomas K, Howells L, Leshem Y, Simpson E, Apfelbacher C, Spuls P, et al.
Br J Dermatol
. 2023 Dec;
190(4):527-535.
PMID: 38123134
Background: The Harmonising Outcome Measures for Eczema (HOME) initiative has agreed upon the Core Outcome Set (COS) for use in atopic dermatitis (AD) clinical trials, but additional guidance is needed...
5.
Renert-Yuval Y, Del Duca E, Arents B, Bissonnette R, Drucker A, Flohr C, et al.
J Eur Acad Dermatol Venereol
. 2023 Sep;
38(1):42-51.
PMID: 37700595
Treat-to-target (T2T) is a pragmatic therapeutic strategy being gradually introduced into dermatology after adoption in several other clinical areas. Atopic dermatitis (AD), one of the most common inflammatory skin diseases,...
6.
Silverberg J, Leshem Y, Calimlim B, McDonald J, Litcher-Kelly L
Curr Med Res Opin
. 2023 Sep;
39(10):1289-1296.
PMID: 37691437
Background: Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by pruritus, skin pain, and sleep impacts, which are only reportable by patients themselves. The goal of this research...
7.
Leshem Y, Simpson E, Apfelbacher C, Spuls P, Thomas K, Schmitt J, et al.
Br J Dermatol
. 2023 Aug;
189(6):710-718.
PMID: 37548315
Background: Core outcome sets (COS) are consensus-driven sets of minimum outcomes that should be measured and reported in all clinical trials. COS aim to reduce heterogeneity in outcome measurement and...
8.
Lam M, Spuls P, Leshem Y, Gerbens L, Thomas K, Arents B, et al.
Br J Dermatol
. 2023 Jul;
189(4):494-496.
PMID: 37434297
No abstract available.
9.
Silverberg J, Simpson E, Calimlim B, Litcher-Kelly L, Li X, Sun X, et al.
Dermatol Ther (Heidelb)
. 2022 Nov;
12(12):2817-2827.
PMID: 36333616
Introduction: Three patient-reported outcome (PRO) questionnaires-Worst Pruritus Numerical Rating Scale (WP-NRS), Atopic Dermatitis Symptom Scale (ADerm-SS), and Atopic Dermatitis Impact Scale (ADerm-IS)-were developed to assess the symptoms and impacts of...
10.
Leshem Y, Chalmers J, Apfelbacher C, Katoh N, Gerbens L, Schmitt J, et al.
JAMA Dermatol
. 2022 Oct;
158(12):1429-1435.
PMID: 36223090
Importance: Measuring outcomes in clinical practice can aid patient care, quality improvement, and real-world evidence generation. The Harmonising Outcome Measures for Eczema (HOME) Clinical Practice initiative is developing a list...